Brief: Ryvu Therapeutics Says Established Exclusive License Agreement With Exelixis To Develop Novel Sting Agonist-Based Targeted Cancer Therapies

Ryvu Therapeutics SA

07/07/2022 05:03

July 7 (Reuters) - Ryvu Therapeutics SA  RVU.WA :
    * EXELIXIS AND RYVU THERAPEUTICS ESTABLISH EXCLUSIVE LICENSE
AGREEMENT TO DEVELOP NOVEL STING AGONIST-BASED TARGETED CANCER
THERAPIES
    * RYVU - EXELIXIS WILL PAY RYVU AN UPFRONT FEE OF $3 MILLION
IN
EXCHANGE FOR CERTAIN RIGHTS TO RYVU'S STING AGONIST SMALL
MOLECULES,SUCH AS ADCS
    * RYVU THERAPEUTICS - RYVU WILL ALSO RETAIN ALL DEVELOPMENT
AND
COMMERCIAL RIGHTS TO DEVELOP ITS STING AGONIST PORTFOLIO AS
STANDALONE SMALL MOLECULES

Source text for Eikon:  ID:nBw2yHDGDa 
Further company coverage:  RVU.WA 

 ((Reuters.Briefs@thomsonreuters.com;))